NXTC
What one share of Nextcure holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies, including antibody-drug conjugates (“ADCs”).
Nextcure’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$9.94 |
|---|---|
| Cash and investments | $3.75 |
| Book value | $2.99 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$16.64 | $2.24 | $3.60 | — | −$34.15 |
| 2019 | $0.40 | −$2.15 | $0.21 | −$2.48 | $0.00 | $11.69 |
| 2020 | $0.81 | −$1.33 | $0.26 | −$1.89 | $0.00 | $10.65 |
| 2021 | — | −$2.51 | $0.09 | −$2.16 | $0.00 | $8.43 |
| 2022 | — | −$2.69 | $0.08 | −$2.02 | $0.00 | $6.03 |
| 2023 | — | −$2.25 | $0.03 | −$1.93 | $0.00 | $4.10 |
| 2024 | — | −$23.88 | $0.20 | −$17.71 | $0.00 | $28.05 |
| 2025 | — | −$19.65 | — | −$17.45 | $0.00 | $9.97 |